InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )

NCT04442178 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

26

Enrollment

INDUSTRY

Sponsor class

Stopped POOR ACCRUAL

Conditions

COVID-19
Lymphocytopenia

Interventions

DRUG: CYT107
DRUG: Placebo

Sponsor

Revimmune

Collaborators

[object Object]
[object Object]